The development of new nuclear medicine and MRI contrast agents is the focus of an alliance signed last month between Epix Medical and Dyax. The two Cambridge, MA, companies have agreed to join forces to spur development of agents to diagnose pulmonary
The development of new nuclear medicine and MRI contrast agents is the focus of an alliance signed last month between Epix Medical and Dyax. The two Cambridge, MA, companies have agreed to join forces to spur development of agents to diagnose pulmonary emboli and deep-vein thrombosis.
Epix is developing MRI agents like its MS-325 cardiovascular imaging agent (SCAN 2/19/97), while Dyax has developed a novel process for identifying proteins that could form the basis for new imaging agents (SCAN 11/20/96). Under the terms of the agreement, the companies will use Dyax's phage-display technology to identify peptides that bind to pulmonary emboli and deep-vein thrombosis.
Epix will fund the phage-display screening program and will provide expertise for developing MRI-specific imaging agents, while Dyax will assume responsibility for developing nuclear medicine agents. Both companies will receive royalties for products resulting from the collaboration.
In other Epix news, the company has begun phase II clinical trials of MS-325. The trials will investigate the safety and preliminary efficacy of the MRI agent for the evaluation of peripheral vascular disease in the carotid, iliac, and femoral arteries. Epix has licensed the agent to Mallinckrodt of St. Louis.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.